Cost-effectiveness of two transdermal nitroglycerin controlled-release systems.
An analysis of the cost-effectiveness of two transdermal nitroglycerin systems utilizing adhesive patches, TDN and ND, was performed by a health-care research and management consulting firm. Better adhesion of TDN produced an estimated 14.5% savings over ND ($22.93 vs $26.82) in wholesale prescription costs for four weeks. Multivariate regression analyses, which controlled for patients' age, sex, body mass index, and study location, did not affect the observed difference in adhesive properties, suggesting that TDN's adhesive superiority is intrinsic to patch function and that it does not depend on other variables.
D000268:Adhesiveness; D000287:Administration, Topical; D000368:Aged; D003362:Cost-Benefit Analysis; D003692:Delayed-Action Preparations; D005260:Female; D006801:Humans; D008297:Male; D005996:Nitroglycerin / Q000008:administration & dosage*
D003692:Delayed-Action Preparations; D005996:Nitroglycerin